Amneal Pharmaceuticals (AMRX) Piper Sandler 36th Annual Healthcare Conference summary

Commercial strategy and product performance

• Crexont achieved 1% market share by year-end, surpassing initial expectations and gaining rapid payer coverage, with projections to exceed 50% coverage next year.

• Focus has shifted from Rytary to Crexont and Ongentys, with minimal expected net revenue fallout in 2025 and peak sales of $300–$500 million forecasted for 2027–2028.

• DHE auto injector for migraines is expected to launch in late first half of next year, targeting $50–$75 million in sales, with commercial support from existing sales teams.

• Unithroid continues to grow due to patient preference for brand consistency in a fluctuating generic market, aiming for 1–2% market share.

Portfolio evolution and pipeline

• Generic injectables contributed $175 million this year, with a target of $300 million next year, driven by complex 505(b)(2) products and hospital-ready formulations.

• 76% of the generics pipeline is now non-oral solids, with a focus on injectables, drug-device combinations, biosimilars, and complex products.

• Biosimilars business is expected to grow from $125 million to $200 million, with new launches and a pipeline of 8–10 products, aiming for vertical integration and international expansion.

• GLP-1 strategy includes partnerships for ultra-long GLP-1s, peptide manufacturing, and a pipeline covering exenatide, liraglutide, Trulicity, and semaglutide, with ambitions to be a leading player over the next 10–15 years.

Capital allocation and business development

• Priority is debt reduction to 4x leverage by year-end and 3x thereafter, while maintaining $200 million in R&D and targeted M&A focused on branded and biosimilar assets.

• CapEx is shifting from generics to biosimilars and GLP-1s, with $150 million planned over three years for new manufacturing capacity.

• Business development targets neurology and oncology, with a focus on niche opportunities and leveraging strong R&D and sales infrastructure.